SECONDARY OSTEOARTHRITIS IN RHEUMATOID ARTHRITIS
https://doi.org/10.17650/1818-8338-2015-1-24-29
Abstract
The paper considers the problems of comorbidities in patients with rheumatoid arthritis (RA). Two or more RA-related conditions were diagnosed according to the results of the QUEST-RA program implemented in 34 countries. Osteoarthritis along with hypertension, hyperlipidemia, and osteoporosis was detected among the most commonly diseases. Owing to expanded diagnostic capabilities, the recognition and treatment of the comorbidities have recently received much attention, as embodied in the draft Association of Rheumatologists of Russia Guidelines for RA management (2014; Part 1). The concept and major characteristics of secondary osteoarthritis in RA are analyzed. It is precisely the inflammatory process and underlying disease-related risk factors, including treatment, that have impact on the development of secondary osteoarthritis and patients’ quality of life as a whole. All this allows an inference about the mechanisms closely intertwined with the underlying disease for the development of secondary osteoarthritis, which initiates cartilage damage and further remodeling. Primary and secondary osteoarthritis was comparatively analyzed. Particular emphasis is placed on current cartilage biomarkers, their diagnostic value and role in monitoring the efficiency of treatment in clinical trials. The paper provides a comparative analysis of detectable serum and urine biomarkers according to the results of the complex analysis made by the National Institutes of Health. Particular attention is given to cartilage oligomeric matrix protein (COMP). Foreign authors’ investigations suggest that there is a relationship between serum COMP levels and disease severity and joint X-ray changes. There is evidence for the efficacy of hyaluronic acid used in the treatment of secondary osteoarthritis in patients with RA.
About the Authors
I. A. Starodubtseva
N.N. Burdenko Voronezh State Medical Academy, Ministry of Health of Russia; 10 Studencheskaya St., Voronezh, 394036, Russia
Russian Federation
Russian Federation
L. V. Vasilyeva
N.N. Burdenko Voronezh State Medical Academy, Ministry of Health of Russia; 10 Studencheskaya St., Voronezh, 394036, Russia
Russian Federation
Russian Federation
References
1. Балабанова Р.М., Иванова М.М., Каратеев Д.Е. Ревматоидный артрит на рубеже веков. В кн.: Избранные лекции по клинической ревматологии. Под ред. В.А. Насоновой, Н.В. Бунчука. М.: Медицина, 2001. С. 61–7. [Balabanova R.M., Ivanova M.M., Karateyev D.E. Rheumatoid arthritis at the turn of the century. In: Selected lectures on clinical rheumatology. V.A. Nasonova, N.V. Bunchuk (eds.). Moscow: Meditsina, 2001. Pp. 61–7. (In Russ.)].
2. Michaud K., Wolfe F. Comorbidities in rheumatoid arthritis. Best Pract Res Clin Rheumatol 2007;21(5):885–906.
3. Grøn K.L., Ornbjerg L.M., Hetland M.L. et al. The association of fatigue, comorbidity burden, disease activity, disability and gross domestic product in patients with rheumatoid arthritis. Results from 34 countries participating in the Quest-RA program. Clin Exp Rheumatol 2014;32(6):869–77.
4. Dougados M., Soubrier M., Antunez A. et al. Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, crosssectional study (COMORA). Ann Rheum Dis 2014;73(1):62–8.
5. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 Update. Arthritis Rheum 2002;46(2):328–46.
6. Klareskog L., Catrina A.I., Paget S. Rheumatoid arthritis. Lancet 2009;373(9664):659–72.
7. Гордеев А.В., Галушко Е.А., Насонов Е.Л. Концепция мультиморбидности в ревматологической практике. Научно-практическая ревматология 2014;(4):362–5. [Gordeyev A.V., Galushko E.A., Nasonov E.L. Multimorbidity concept in rheumatological practice. Nauchno-prakticheskaya revmatologiya = Scientific and Practical Rheumatology 2014;(4):362–5. (In Russ.)].
8. Панафидина Т.А., Кондратьева Л.В., Герасимова Е.В. и др. Коморбидность при ревматоидном артрите. Научно-практическая ревматология 2014;(3):283–9. [Panafidina T.A., Kondratiyeva L.V., Gerasimova E.V. et al. Comordibity with rheumatoid arthritis. Nauchno-prakticheskaya revmatologiya = Scientific and Practical Rheumatology 2014;(3):283–9. (In Russ.)].
9. Насонов Е.Л., Каратеев Д.Е., Балабанова Р.М. Ревматоидный артрит. В кн.: Ревматология: Национальное руководство. Под ред. Е.Л. Насонова, В.А. Насоновой. М.: ГЭОТАР-Медиа, 2008. C. 290–331. [Nasonov E.L., Karateyev D.E., Balabanova R.M. Rheumatoid arthritis. In: Rheumatology: national guideline. E.L. Nasonov, V.A. Nasonova (eds.). Moscow: GEOTAR-Media, 2008. Pp. 290–331. (In Russ.)].
10. Насонов Е.Л., Мазуров В.И., Каратеев Д.Е. и др. Проект рекомендаций по лечению ревматоидного артрита Общероссийской общественной организации «Ассоциация ревматологов России»-2014 (часть 1). Научно-практическая ревматология 2014; (5):477–94. [Nasonov E.L., Mazurov V.I., Karateyev D.E. et al. Draft recommendations for treatment of rheumatoid arthritis of the All-Russian Public Association “Russian Association of Rheumatogists”, 2014 (Part 1). Nauchno-prakticheskaya revmatologiya = Scientific and Practical Rheumatology 2014;(5):477–94. (In Russ.)].
11. Балабанова Р.М. Роль интерлейкина-1 при остеоартрозе и возможности его блокирования. Современная ревматология 2011;(1):58–63. [Balabanova R.M. The role of interleukin-1 with osteoarthritis and possibilities of its blocking. Sovremennaya revmatologiya = Modern Rheumatology 2011;(1):58–63. (In Russ.)].
12. Балабанова Р.М., Алексеева Л.И. Ингибиция интерлейкина-1 – новый подход к лечению остеоартроза. Медицинский совет 2010;(7–8):40–1. [Balabanova R.M., Alexeyeva L.I. Interleukin-1 inhibition as a new approach to osteoarthritis treatment. Meditsinskiy sovet = Medical Council 2010;(7–8):40–1. (In Russ.)].
13. Галушко Е.А., Большакова Т.Ю., Виноградова И.Б. и др. Структура ревматических заболеваний среди взрослого населения России по данным эпидемиологического исследования (предварительные результаты). Научно-практическая ревматология 2009;(1):117. [Galushko E.A., Bolshakova T.Yu., Vinogradova I.B. et al. Structure of rheumatoid diseases among adult population of russia in accordance with the results of the epidemiological study (preliminary results). Nauchno-prakticheskaya revmatologiya = Scientific and Practical Rheumatology 2009;(1):117. (In Russ.)].
14. Дроздов В.Н. Остеоартроз (остеоартрит). Consilium medicum 2004;(12):45–9. [Drozdov V.N. Osteoarthritis. Consilium medicum 2004;(12):45–9. (In Russ.)].
15. Алексеева Л.И. Современные представления о диагностике, лечении и профилактике остеоартроза. Русский медицинский журнал 2000;8(9):377–82. [Alexeyeva L.I. Modern ideas of diagnostics, treatment, and prevention of osteoarthritis. Russkiy meditsinskiy zhurnal = Russian Medical Journal 2000;8(9):377–82. (In Russ.)].
16. FNIH Osteoarthritis Biomarkers Consortium Project. Available at URL: http:// oarsi.org/sites/default/files/fnih_oa_ biomarkers_project_update.pdf.
17. Sugiyama S., Itokazu M., Suzuki Y., Shimizu K. Procollagen II C propeptide level in the synovial fluid as a predictor of radiographic progression in early knee osteoarthritis. Ann Rheum Dis 2003;62(1):27–32.
18. Vingsbo-Lundberg C., Saxne T., Ollson H., Holmdahl R. Increased serum levels of cartilage oligomeric matrix protein in chronic erosive arthritis in rats. Arthritis Rheum 1998;41(3):544–50.
19. Joosten L.A., Helsen M.M., Saxne T. et al. IL-1 alpha beta blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNF-alpha blockade only ameliorates joint inflammation. J Immunol 1999;163(9):5049–55.
20. Månsson B., Carey D., Alini M. et al. Cartilage and bone metabolism in rheumatoid arthritis. Differences between rapid and slow progression of disease identified by serum
Review
For citations:
Starodubtseva I.A., Vasilyeva L.V. SECONDARY OSTEOARTHRITIS IN RHEUMATOID ARTHRITIS. The Clinician. 2015;9(1):24-29. (In Russ.) https://doi.org/10.17650/1818-8338-2015-1-24-29
Views:
1621
Email this article 